Afrin Pediatric Nasal Drops, Nasal Drops, Nasal Solution, Nasal Spray

Afrin is a direct-acting sympathomimetic which has vasoconstrictor effect on mucosal blood vessels when applied topically and in turn reduces oedema of the nasal mucosa.

Uses

Afrin Hydrochloride is applied topically to relieve nasal congestion associated with acute or chronic rhinitis, common cold, sinusitis, and hay fever or other allergies. It is also used as nasal decongestant in otitis media.

Afrin is also used to associated treatment for these conditions: Acquired Blepharoptosis, Allergic Rhinitis (AR), Nasal Congestion, Postoperative Hemorrhages, Rhinorrhoea, Sinus Congestion, Acute Rhinitis, Persistent facial erythema, Airway visualization

Trade Name Afrin
Generic Oxymetazoline
Other Names Oximetazolinum, Oxymetazolina, Oxymetazoline, Oxymétazoline, Oxymetazolinum, Oxymethazoline, Oxymetozoline
Weight 025%, 05%, , 0.025%, 0.05%, 05mg/ml
Type Pediatric Nasal Drops, Nasal Drops, Nasal Solution, Nasal Spray
Formula C16H24N2O
Weight Average: 260.3746
Monoisotopic: 260.1888634
Protein binding

In vitro, oxymetazoline is 56.7% to 57.5% bound to human plasma proteins.

Therapeutic Class Nasal Anti-histamine preparations, Nasal Decongestants & Other Nasal Preparations
Manufacturer Aristopharma Ltd, Merck Sharp & Dohme Pharma, Bayer Indonesia
Available Country Bangladesh, United States, Indonesia, Netherlands,
Last Updated: June 23, 2021 at 11:24 am

Dosage

Afrin dosage

Adults and children 6 years of age and older: 2-3 drops or sprays in each nostril twice daily for 3-5 days.

Children of age 2-6 years: 2-3 drops in each nostril twice daily for 3-5 days. Sprays are generally unsuitable for young children because of the small size of their nostrils. The drug is not recommended in children under the age of 2 years.

The nasal spray can be used with the patient in the upright position. Sprays are generally unsuitable for young children because of the small size of their nostril. A treatment course should not normally exceed three to five days, and on no account should it be continued for longer than two weeks because of the risk of developing "rhinitis medicamentosa".

Side Effects

Transient burning, dryness of the nasal mucosa, sneezing, Nervousness, dizziness, headache, Hypertension, palpitation or reflex bradycardia.

Precaution

  • Prolonged use may result in rebound congestion.
  • Since oxymetazoline has systemic adverse effects, it should be used with caution in patients with
  • Hypertension, cardiovascular disease or hyperthyroidism or in those receiving MAO inhibitors.

Interaction

Monoamine oxidase inhibitors (MAOIs): Concomitant use of oxymetazoline and MAOI can result in  hypertensive reaction. 

Tricyclic antidepressants (TCAs): TCAs may increase the effects of oxymetazoline on blood pressure.

Food Interaction

No interactions found.

Volume of Distribution

There is limited information on the volume of distribution of oxymetazoline.

Half Life

Following ocular administration in healthy adults, the mean terminal half-life was 8.3 hours, ranging from 5.6 to 13.9 hours.

The terminal half-life of oxymetazoline following nasal administration of the combination product containing tetracaine and oxymetazoline in adult subjects is approximately 5.2 hours.

Clearance

There is limited information on the clearance rate of oxymetazoline.

Pregnancy & Breastfeeding use

Pregnancy: Safe use of oxymetazoline during pregnancy has not been established; it should be avoided by pregnant women.

Nursing Mother: It is not known whether oxymetazoline is secreted in human breast milk; caution is advised.

Contraindication

Contraindicated in patients hypersensitive to Oxymetazoine Hydrochloride.

Acute Overdose

Following a proper application, systemic action is unlikely. If, however, some of the drops are swallowed, systemic effect can be produced. Symptoms include rapid, irregular heartbeat, headache, dizziness, increased sweating, nervousness. Such symptoms are more likely to be seen in young children.

Afrin contains Oxymetazoline see full prescribing information from innovator Monograph